IN2012DN00733A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00733A
IN2012DN00733A IN733DEN2012A IN2012DN00733A IN 2012DN00733 A IN2012DN00733 A IN 2012DN00733A IN 733DEN2012 A IN733DEN2012 A IN 733DEN2012A IN 2012DN00733 A IN2012DN00733 A IN 2012DN00733A
Authority
IN
India
Prior art keywords
polypeptides
medicaments
well
relates
present
Prior art date
Application number
Inventor
Fred Hofmann
Jurgen Frevert
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of IN2012DN00733A publication Critical patent/IN2012DN00733A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)

Abstract

The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein said polypeptide comprises a at least one degradation signal in the light chain as well as vectors and host cells comprising the said polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising said polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments..
IN733DEN2012 2009-07-02 2010-07-01 IN2012DN00733A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27019809P 2009-07-02 2009-07-02
EP09164365 2009-07-02
PCT/EP2010/059398 WO2011000929A1 (en) 2009-07-02 2010-07-01 Neurotoxins exhibiting shortened biological activity

Publications (1)

Publication Number Publication Date
IN2012DN00733A true IN2012DN00733A (en) 2015-06-19

Family

ID=40911088

Family Applications (1)

Application Number Title Priority Date Filing Date
IN733DEN2012 IN2012DN00733A (en) 2009-07-02 2010-07-01

Country Status (14)

Country Link
US (4) US8586329B2 (en)
EP (1) EP2449101B1 (en)
JP (2) JP6059986B2 (en)
KR (2) KR20120104140A (en)
CN (1) CN102471765B9 (en)
AU (1) AU2010267963B2 (en)
BR (1) BRPI1014253A2 (en)
CA (1) CA2763692A1 (en)
ES (1) ES2693705T3 (en)
IL (1) IL216414A (en)
IN (1) IN2012DN00733A (en)
MX (2) MX2011013014A (en)
RU (1) RU2582266C2 (en)
WO (1) WO2011000929A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (en) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutic with a botulinum neurotoxin
AR061669A1 (en) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa HIGH FREQUENCY THERAPY APPLICATION WITH BOTULIN TOXIN
WO2012125652A2 (en) * 2011-03-14 2012-09-20 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
SG11201402131TA (en) * 2011-11-09 2014-08-28 Merz Pharma Gmbh & Co Kgaa Neurotoxins exhibiting shortened biological activity
WO2014029497A1 (en) 2012-08-20 2014-02-27 Merz Pharma Gmbh & Co. Kgaa Novel method for the manufacturing of recombinant proteins harbouring an n-terminal lysine
BR112015007231A2 (en) 2012-10-16 2017-07-04 Almirall Sa pyrroltriazinone derivatives as pi3k inhibitors
KR102083373B1 (en) 2012-11-21 2020-03-03 입센 바이오이노베이션 리미티드 Methods for the manufacture of proteolytically processed polypeptides
MX365711B (en) 2013-04-18 2019-06-11 Fond Telethon Effective delivery of large genes by dual aav vectors.
PL2952205T3 (en) 2014-06-06 2018-01-31 Kleiner Fisman Galit Botulinum toxin for use in the treatment of paratonia
US20170112907A1 (en) 2014-06-13 2017-04-27 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US20170189500A1 (en) 2014-06-13 2017-07-06 Merz Pharma Gmbh & Co. Kgaa Use of recombinant clostridial neurotoxins for the treatment of patients having certain muscle-related disorders
US20170128551A1 (en) * 2014-06-13 2017-05-11 Klaus Fink Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
WO2015188944A1 (en) * 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
JP6798993B2 (en) 2014-12-23 2020-12-09 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン Botulinum toxin prefilled container
PL3242884T3 (en) 2015-01-09 2021-08-16 Ipsen Bioinnovation Limited Cationic neurotoxins
CA2979120A1 (en) * 2015-03-03 2016-09-09 Fondazione Telethon Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
WO2016168740A2 (en) * 2015-04-16 2016-10-20 Spencer Juliet V Detection of human cytomegalovirus in breast cancer
TW201718627A (en) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 Recombinant clostridial neurotoxin, a use thereof, and a method for generating the same, a pharmaceutical composition comprising the same and a precursor corresponding to the same, a nucleic acid sequence encoding the precursor and a method for obtaining
KR101793328B1 (en) * 2015-07-03 2017-11-03 씨제이제일제당 (주) A microorganism having enhanced L-lysine productivity and a method of producing L-lysine using the same
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
WO2017148915A1 (en) 2016-03-02 2017-09-08 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
KR102423088B1 (en) * 2016-06-02 2022-07-21 호유 가부시키가이샤 Egg allergy antigen
TWI737742B (en) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 Botulinum toxin prefilled syringe system, kit having the same and use thereof
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
CN110506111B (en) * 2016-11-28 2024-08-23 希-莱科塔有限公司 Trehalose phosphorylase
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
WO2019178116A1 (en) 2018-03-12 2019-09-19 Conagen Inc. Biosynthetic production of steviol glycosides rebaudioside j and rebaudioside n
MX2020009507A (en) * 2018-03-13 2020-10-22 Smivet B V Single domain antibodies binding to tetanus neurotoxin.
US10751399B2 (en) * 2018-03-20 2020-08-25 Cho Pharma Usa, Inc. Chimeric antigen receptors that bind to SSEA4 and uses thereof
WO2019211969A1 (en) * 2018-05-02 2019-11-07 天野エンザイム株式会社 Modified esterase and application therefor
CN108588087B (en) * 2018-05-16 2022-06-03 南京农业大学 A gene GmLecRK-R for improving plant disease resistance and its application
EP3688151A1 (en) * 2018-12-21 2020-08-05 Fornia BioSolutions, Inc. Variant g6p g7p glucoamylase compositions and methods
CN109998055B (en) * 2019-04-09 2022-03-25 黑龙江省科学院大庆分院 Hemp seed antioxidant polypeptide chewable tablet and preparation method thereof
CN110100945B (en) * 2019-05-05 2022-05-03 黑龙江省科学院大庆分院 Hemp blood fat reducing peptide composition and application thereof
WO2020253537A1 (en) * 2019-06-21 2020-12-24 苏州克睿基因生物科技有限公司 Method and kit for detecting african swine fever virus
CN110295150A (en) * 2019-07-17 2019-10-01 天津润德生物科技有限公司 A kind of gland dependovirus virus recombinant plasmid, recombinant virus and construction method
CN110540996B (en) * 2019-08-29 2022-01-28 华中农业大学 Procambarus clarkii i-type lysozyme gLysi2 gene, gLysi2 protein coded by same and application thereof
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
CN110643616A (en) * 2019-10-22 2020-01-03 云南省烟草农业科学研究院 Cloning and application of tobacco nicotine synthesis regulation gene NtERF91
WO2021167107A1 (en) * 2020-02-22 2021-08-26 Ｊｃｒファーマ株式会社 Human transferrin receptor binding peptide
CN112540178B (en) * 2020-08-06 2023-12-19 武汉天德生物科技有限公司 Immunohistochemical kit for detecting early senile dementia and use method thereof
CN112662644B (en) * 2021-01-19 2022-04-22 华南理工大学 Diglycerol phosphate phosphodiesterase mutant and application thereof
CN113899907B (en) * 2021-09-07 2023-06-27 中国农业科学院油料作物研究所 Method for efficiently screening aflatoxin green prevention and control materials in one step and application thereof
CN115109759B (en) * 2022-06-24 2024-05-03 浙江工业大学 Carbonyl reductase LsCR mutant, engineered bacteria and their application in asymmetric reduction of carbonyl compounds to prepare chiral alcohols
CN117741160B (en) * 2023-12-21 2024-07-12 汉王科技股份有限公司 Use of olfactory receptors for the recognition of ethanol and method for detecting ethanol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
DE10333317A1 (en) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulation for protein medicines without the addition of human serum albumin (HSA)
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US7825233B2 (en) * 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
US20060004334A1 (en) 2004-06-30 2006-01-05 Kimberly-Clark Worldwide, Inc. Stabilized absorbent structures
CN102139099A (en) 2004-07-26 2011-08-03 莫茨药物股份两合公司 Therapeutic composition with a botulinum neurotoxin

Also Published As

Publication number Publication date
AU2010267963A1 (en) 2011-12-22
CA2763692A1 (en) 2011-01-06
US20170072030A1 (en) 2017-03-16
WO2011000929A1 (en) 2011-01-06
US9511114B2 (en) 2016-12-06
KR101818895B1 (en) 2018-01-15
JP2015231378A (en) 2015-12-24
AU2010267963B2 (en) 2015-09-24
US8586329B2 (en) 2013-11-19
US20140045760A1 (en) 2014-02-13
BRPI1014253A2 (en) 2016-04-12
CN102471765B (en) 2016-05-11
IL216414A (en) 2016-08-31
EP2449101A1 (en) 2012-05-09
RU2582266C2 (en) 2016-04-20
JP6059986B2 (en) 2017-01-11
US9827298B2 (en) 2017-11-28
US9193771B2 (en) 2015-11-24
MX352265B (en) 2017-11-16
ES2693705T3 (en) 2018-12-13
KR20170016529A (en) 2017-02-13
US20120107362A1 (en) 2012-05-03
IL216414A0 (en) 2012-02-29
EP2449101B1 (en) 2018-10-10
HK1171246A1 (en) 2013-03-22
KR20120104140A (en) 2012-09-20
JP2012531191A (en) 2012-12-10
CN102471765B9 (en) 2016-07-27
CN102471765A (en) 2012-05-23
MX2011013014A (en) 2012-01-27
RU2012103376A (en) 2013-08-10
US20160030511A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
IN2012DN00733A (en)
MX2014005544A (en) Neurotoxins exhibiting shortened biological activity.
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins
MX359953B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein.
WO2010020766A3 (en) Interleukin fusion polypeptides
MY161268A (en) PEPTIDE OR PEPTIDE COMPLEX BINDING TO α2 INTEGRIN AND METHODS AND USES INVOLVING THE SAME
MX374682B (en) 4-1BB BINDING MOLECULES.
MX361728B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen.
MX2011013457A (en) Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer.
ATE548381T1 (en) MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES WITH INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF
WO2010099477A3 (en) Polypeptide structural motifs associated with cell signaling activity
EA201171148A1 (en) ANTI-TELE-ANTAGONIST, SPECIFIC FOR THE ALPHA-4-BETA-7 HETERODIMER
TN2012000167A1 (en) Human il-23 antigen binding proteins
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
IL202443B (en) Rage fusion protein, nucleic acid encoding the same and pharmaceutical composition comprising the protein
WO2011123683A3 (en) Protease activated cytokines
MX351502B (en) Albumin binding antibodies and binding fragments thereof.
EA201590195A1 (en) DNA CODED LIBRARIES CONTAINING LINKS TO ENCODATING OLIGONUCLEOTIDE, NOT AVAILABLE FOR POLYMERASE READING
PH12016500275A1 (en) Antibodies
WO2011002977A3 (en) Genetically encoded photomanipulation of protein and peptide activity
EA201590162A1 (en) OspA MUTANT FRAGMENTS AND RELATED METHODS AND APPLICATIONS
WO2013052946A3 (en) Genetically encoded biosensors
WO2008133141A1 (en) Osmotin recombinant protein, method for production of the same, and use of the same
WO2010001134A3 (en) Insulin fusion polypeptides
EP2620453A4 (en) SAMB FUSION PROTEIN, ITS ENCODING GENE AND APPLICATION